• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Faeth Therapeutics, Inc. - Common Stock (NQ:FTH)

7.880 -0.810 (-9.32%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 419,109
Open 8.520
Bid (Size) 7.730 (100)
Ask (Size) 10.50 (600)
Prev. Close 8.690
Today's Range 7.840 - 9.133
52wk Range 7.840 - 42.14
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
November 16, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
November 11, 2026
From Faeth Therapeutics
Via Business Wire

Performance

52-Week Range 81.3% below 52-week high
7.880
7.8452W Low 42.1452W High
1 Week 23.2% below 1-week high
7.841W Low 10.261W High

Faeth Therapeutics, Inc. - Common Stock (FTH) traded between $7.84 and $42.14 over the past 52 weeks and last traded at $7.88, 81.3% below its 52-week high. Over the past week it ranged between $7.84 and $10.26.

Past 12 Months
-15.1%
-60.8%
-77.3%
-45.8%
-45.8%
-45.8%
1W -$1.40
1M -$12.22
3M -$26.83
6M -$6.65
YTD -$6.65
1Y -$6.65

FTH was -45.8% over the past year, -45.8% over six months, -45.8% year to date, -15.1% in the last week.

12 Months vs Market
FTH
-45.8%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months FTH returned -45.8% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 0.84× 3-mo avg
Today 419,109 3-mo avg 500.4K
1W
554.6K
1M
716.1K
3M
500.4K
6M
395.1K
YTD
395.1K
1Y
395.1K

FTH most recently traded 419,109 shares against a 3-month average daily volume of 500.4K.

More News

Read More
US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Losers ↗
November 09, 2026
Via Chartmill
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98% ↗
November 09, 2026
Via Chartmill
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
November 09, 2026
Via Chartmill
Premarket Movers on Nov. 9, 2026: Small-Cap Gainers and Losers ↗
November 09, 2026
Via Chartmill
News headline image
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
November 09, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
After-Hours Market Movers: Gainers and Decliners From Today's U.S. Session ↗
November 06, 2026
Via Chartmill
News headline image
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
November 06, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
November 03, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
October 27, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
October 23, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 22, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
October 19, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout ↗
October 07, 2026
Via MarketBeat
News headline image
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
September 17, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
September 08, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
August 17, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
August 14, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From Faeth Therapeutics, Inc.
Via Business Wire
News headline image
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
August 07, 2026
From Faeth Therapeutics
Via Business Wire
News headline image
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
August 04, 2026
From Faeth Therapeutics
Via Business Wire

Frequently Asked Questions

Is Faeth Therapeutics, Inc. - Common Stock publicly traded?
Yes, Faeth Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Faeth Therapeutics, Inc. - Common Stock trade on?
Faeth Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Faeth Therapeutics, Inc. - Common Stock?
The ticker symbol for Faeth Therapeutics, Inc. - Common Stock is FTH on the Nasdaq Stock Market
What is the current price of Faeth Therapeutics, Inc. - Common Stock?
The current price of Faeth Therapeutics, Inc. - Common Stock is 7.880
When was Faeth Therapeutics, Inc. - Common Stock last traded?
The last trade of Faeth Therapeutics, Inc. - Common Stock was at 11/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap